Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hayden

Showing results (511-520 of 538) with videos related to

Pageof 54
Sort By:
European Journal of Haematology|April 21, 2023
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT studyNico Gagelmann, Dirk-Jan Eikema, Linda Koster, et al.
European Journal of Haematology|February 13, 2021
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMTLaurent Garderet, Giulia Sbianchi, Simona Iacobelli, et al.
British Journal of Haematology|February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Bone Marrow Transplantation|May 24, 2020
Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
Haematologica|December 22, 2022
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experienceDai Chihara, Luuk Gras, Nienke Zinger, et al.
Cancers|July 27, 2024
Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation-A Multicenter Report by the Polish Myeloma Study GroupJoanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Magdalena Topczewska, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
Bone Marrow Transplantation|February 16, 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMTJoanna Drozd-Sokołowska, Luuk Gras, Nienke Zinger, et al.
Bone Marrow Transplantation|January 31, 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMTMeral Beksac, Diderik-Jan Eikema, Linda Koster, et al.
Transplantation and Cellular Therapy|October 2, 2023
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)Guillermo Ortí, Luuk Gras, Linda Koster, et al.
Pageof 54

Showing results (511-520 of 538) with videos related to

Sort By:
Pageof 54
European Journal of Haematology|April 21, 2023
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT studyNico Gagelmann, Dirk-Jan Eikema, Linda Koster, et al.
European Journal of Haematology|February 13, 2021
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMTLaurent Garderet, Giulia Sbianchi, Simona Iacobelli, et al.
British Journal of Haematology|February 15, 2022
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019Dawn Swan, Patrick J Hayden, Dirk-Jan Eikema, et al.
Bone Marrow Transplantation|May 24, 2020
Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT surveyLeopold Sellner, Johannes Schetelig, Linda Koster, et al.
Haematologica|December 22, 2022
Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experienceDai Chihara, Luuk Gras, Nienke Zinger, et al.
Cancers|July 27, 2024
Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation-A Multicenter Report by the Polish Myeloma Study GroupJoanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Magdalena Topczewska, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
Bone Marrow Transplantation|February 16, 2022
Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation-study on behalf of CMWP of the EBMTJoanna Drozd-Sokołowska, Luuk Gras, Nienke Zinger, et al.
Bone Marrow Transplantation|January 31, 2024
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMTMeral Beksac, Diderik-Jan Eikema, Linda Koster, et al.
Transplantation and Cellular Therapy|October 2, 2023
Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)Guillermo Ortí, Luuk Gras, Linda Koster, et al.
Pageof 54